Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


More Hope, And More Demands, For Pancreatic Cancer Pipeline

Executive Summary

ASCO reflected diverse lay of the land for the challenging development space, with new drugs coming from Merrimack, Halozyme, Threshold and a range of immunotherapy combinations. Meanwhile, Celgene’s Abraxane appears to be on blockbuster track.

You may also be interested in...

Imperfect Dataset Bolsters Halozyme's Biomarker Plan For PEGPH20

While not perfect, the latest Phase II data for the stromal depleting agent PEGPH20 give cause for optimism for hyaluronan as a biomarker in pancreatic cancer and for Halozyme's Phase III strategy.

Biomarkers For Pancreatic Cancer To Be Tested In Multi-drug Collaborative Study

Patient advocacy group is spearheading the genomics-driven trial, which will assess if stratification may finally be possible in pancreatic cancer.

Cancer Trials Should Show Minimum 20% Overall Survival Benefit, ASCO Suggests

American Society of Clinical Oncology draft recommendations provide benchmarks for Phase III oncology drug trials, including a minimum 20% improvement in overall survival, with a higher bar for certain diseases.


Related Companies

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts